Cowen analyst Marc Frahm downgraded Odonate Therapeutics (NASDAQ: ODT) from Outperform to Market Perform.The analyst commented, "Odonate conducted a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE